// Post a message

Replying to:

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.

Zhang L, Wu B, Baruchel S. from the New Agent and Innovative Therapy Program, and the Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canadahave published in Translational Oncology an artivle entitled : Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models. In this article, they show using a panel of neuroblastoma cell lines carrying various ALK genetic aberrations that (...)

pre-moderation

This forum is moderated beforehand: your contribution will only appear after being validated by a site administrator.

Any message or comment?
  • (To create paragraphs, you simply leave blank lines.)

Who are you? (optional)